52959-289 : Viracept 250 mg Oral Tablet
NDC: | 52959-289 |
Labeler: | H.j. Harkins Company, Inc. |
Product Type: | Human Prescription Drug |
Drug Name: | Viracept |
Dosage Form: | Oral Tablet, Film Coated |
Application #: | NDA020779 |
Rev. Date: |
Appearance:
Markings: | VIRACEPT;250;mg |
Shapes: |
Oval |
Colors: |
Blue |
Size (mm): | 19 |
Segments: * | 1 |
* Segments = the number of equally sized pieces which the pill can be broken into. In this case, a value of 1 indicates a solid pill with no score lines. |
The above image is provided by the U.S. National Library of Medicine (NLM) and is not part of the official label.
NDC Package Codes:
- 52959-289-06: 6 TABLET, FILM COATED IN 1 BOTTLE (52959‑289‑06)
- 52959-289-30: 30 TABLET, FILM COATED IN 1 BOTTLE (52959‑289‑30)
Active Ingredients:
- Nelfinavir Mesylate
Dosage Strength:
- 250 mg
Inactive Ingredients:
- Calcium Silicate
- Crospovidone
- Magnesium Stearate
- Hypromelloses
- Triacetin
- Fd&c Blue No. 2
Pharmaceutical Classes:
- HIV Protease Inhibitors [MoA]
- Protease Inhibitor [EPC]
- Cytochrome P450 3A Inhibitors [MoA]
Related Products:
Based on records with the same trade name.- 24236-287 Viracept 625 mg Oral Tablet by Remedyrepack Inc.
- 53808-0809 Viracept 625 mg Oral Tablet by State of Florida Doh Central Pharmacy
- 55289-477 Viracept 250 mg Oral Tablet by Pd-rx Pharmaceuticals, Inc.
- 63010-010 Viracept 250 mg Oral Tablet by Agouron Pharmaceuticals Inc
- 63010-011 Viracept 50 mg/g Oral Powder by Agouron Pharmaceuticals Inc
- 63010-027 Viracept 625 mg Oral Tablet by Agouron Pharmaceuticals Inc
NDC QR Code
Scan the QR code below to easily reference this data in the future:< Prev: 52959-282Next: 52959-295 >
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.